CoChat

Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells

Open access

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; none of the 17 sources its claims cite is checked for support yet.

Abstract

B-cell lines and primary PBMCs are notoriously hard to transfect, thus making genome editing, ectopic gene expression, or gene silencing experiments particularly tedious. Here we propose a novel efficient and reproducible protocol for electrotransfection of lymphoblastoid, B-cell lymphoma, leukemia cell lines, and B cells from PBMCs. The proposed protocol requires neither costly equipment nor expensive reagents; it can be used with small or large plasmids. Transfection and viability rates of about 79% and 58%, respectively, have been routinely achieved by optimizing the salt concentration in the electrotransfection medium and the amount of plasmid used. A validation of the protocol was obtained via the generation of a TP53-/- RPMI8866 lymphoblastoid cell line which should prove useful in future hematological and blood cancer studies.

Overview

CoChat Summary

TL;DR

The paper presents an optimized electrotransfection protocol for hard-to-transfect human B-cell lines and PBMCs, using salt concentration and plasmid amount adjustments to improve GFP expression and viability. It validates the protocol by generating TP53−/− RPMI8866 cells via CRISPR/Cas9 without viral vectors.

Key findings

  • In RPMI8866 LCL, using 50 µg pCMV-GFP in 50% water/50% S-MEM with 1300 V/cm, eight 100 µs pulses at 1 Hz gave 79.2±4.6% transfection and 58.3±4.8% viability, compared with 55.3±2.3% and 68±3% using 10 µg under the same salt conditions.
  • The protocol yielded transfection efficiency of 41–73% and viability of 20–55% in Priess and Remb1 LCLs, BL2 Burkitt lymphoma, and RS4;11 acute lymphoblastic leukemia cell lines.
  • For PBMCs, a modified protocol (50% SHM, 4-mm cuvettes, 1500 V/cm, 24 pulses) gave 1.5±0.5% transfection and 30.4±1.9% viability at 24 h; among transfected/living cells, 83.7±3.0% were CD3+ T cells and 7.1±2.0% CD19+ B cells.
  • Large Cas9-GFP plasmid (13.5 Kbp) gave lower transfection: 1.1±0.1% with 10 µg and 4.6±0.8% with 50 µg, with viability of 64.3±4.3% and 61.7±1.2%, respectively. The protocol generated TP53−/− RPMI8866 clones with PCR amplicons of 350 bp and 400 bp, no p53 mRNA/protein, and reduced p21 expression.

Methods

  • Optimization in RPMI8866 LCL: cells were transferred to fresh medium 48 h before electrotransfection; 5×10⁵ cells were resuspended in 100 µL of S-MEM, water, and pCMV-GFP (3.5 Kbp) and electrotransfected with a Cliniporator and 1-mm cuvettes at 1300 V/cm, eight 100 µs pulses at 1 Hz. Efficiency and viability were measured 48 h later by flow cytometry (BD Accuri C6), with viability calculated relative to non-electrotransfected controls.
  • Salt/plasmid variation: 10 µg pCMV-GFP was tested with different water/S-MEM ratios, and 50 µg was tested in 50% water/50% S-MEM; the protocol was applied to other B-cell lines and PBMCs. PBMCs were purified by Pancoll density gradient from healthy donors; modified conditions used 400 µL total volume, 50% SHM, 4-mm cuvettes, 1500 V/cm, 24 pulses, and analysis at 24 and 48 h.
  • Genome editing: 8×10⁶ RPMI8866 cells were electrotransfected with 30 µg Cas9-GFP and 20 µg phU6 plasmids encoding two gRNAs (10 µg each) in 400 µL in 4-mm cuvettes; GFP+ cells were sorted 48 h later at one cell per well, and clones were screened by PCR for TP53 exons 2 and 11 and confirmed by qRT-PCR and Western blot for p53 and RT-qPCR for p21. Statistics used means ± SEM, at least two biological replicates, and one-way ANOVA with Bonferroni post-test.

Limitations

  • The paper does not state a dedicated limitations section; no author-stated limitations are provided.
  • Evident from the text: PBMC transfection remained low (1.5±0.5% at 24 h) with 30.4±1.9% viability, and the transfected/living population was mostly CD3+ T cells (83.7±3.0%) rather than CD19+ B cells (7.1±2.0%), indicating limited efficiency for primary B cells.
  • Evident from the text: large plasmid (Cas9-GFP, 13.5 Kbp) transfection rates were much lower (1.1±0.1% with 10 µg; 4.6±0.8% with 50 µg) than small pCMV-GFP, and optimized conditions reduced viability (58.3±4.8% vs 68±3% with 10 µg).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41434-020-00194-x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 13 Not checked · 24 Own results and interpretations

13 more claims

Create a free account to see all 37 claims and to verify the 15 references still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 19 references

Cited by

See all 31

Metadata

Authors
Canoy, R. J., André, F., Shmakova, A., Wiels, J., Lipinski, M., Vassetzky, Y., & Germini, D.
Affiliations
Centre National de la Recherche Scientifique (FR)
Corresponding author
  • Vassetzky, Yegor
  • Germini, Diego
Venue
Gene Therapy
Published
2020-09-30
Volume
30
Issue
1-2
Pages
167-171
ISSN
  • 0969-7128 (ISSN-L)
  • 1476-5462
OpenAlex
W3091057210
Cited by
31
References
19
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 9
FWCI
2.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
ANRS INSERM
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
electrotransfection, human B cells, primary B cells, genome editing, ectopic expression, gene silencing, lymphoblastoid cell lines, B-cell lymphoma cell lines, leukemia cell lines, plasmid transfection, TP53 knockout
MeSH terms
Ectopic Gene Expression, Gene Editing, Cell Line, Humans, Plasmids, Transfection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells. https://app.cochat.ai/papers/10.1038/s41434-020-00194-x
The paper
Canoy, R. J., André, F., Shmakova, A., Wiels, J., Lipinski, M., Vassetzky, Y., & Germini, D. (2023). Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells. Gene Therapy. https://doi.org/10.1038/s41434-020-00194-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.